Cambridge Sciences Pharmaceuticals (CSP) latest prescription do drugs, Metabical, was in the final stages of receiving FDA approval. This revolutionary drug, claims CSPs CMO, Bernard Long, would be the first and only prescription drug to cope with FDA approval to meet the needs of individuals who wish to loose amongst 10 to 30 pounds of weight without facing the risks of any study side effects.
The senior director of marketing, Barbara Printup, was responsible for managing the upcoming drive of this drug in the United States. She is currently trying to render out the pricing, packaging and demand forecast for this new drug as part of the launch outline. The pricing and packaging strategy was especially important to Printup since, unlike other drugs in CSPs portfolio, health insurance providers would non be covering the cost for Metabical for the end- exploiters due to the exclusion of anti-obesity drugs.
Packaging strategy
Due to the exclusion of anti-obesity drugs from health insurance coverage, the packaging of Metabical needed to be strategic much(prenominal) that the maximum percentage of CSPs target market would be able to afford the drug.
Ideally, Printup would like to package the drug for a period of 12 weeks since FDA testing showed that the maximum effectiveness of Metabical was sight by the majority of the users within that time-frame. Thereafter, the weight loss accomplished by the drug was very minimal. In light of two of these facts, I feel that Printup should proceed with a 4 week packaging. This would greatly increase the affordability of the drug and simultaneously ensure that the user does not have to get too many refills, which baron lead to the user dropping off from the medication and not realizing the full benefits of Metabical.If you want to get a full essay, magnitude it on our website: Orderessay
If you want to get a full essay, wisit our page: write my essay .
No comments:
Post a Comment